Business context and reporting period
Important entity mismatch: The supplied filing is Foresight Acquisition Corp.’s Form 10-Q, not a filing by P3 Health Partners Inc. Foresight was a blank-check company formed to pursue a business combination. This report covers the three months ended March 31, 2021; it does not provide P3-specific financial results.
Foresight completed its IPO on February 12, 2021, raising $316.25 million gross from public units and placing $316.25 million in trust. It also sold $8.325 million of private-placement units. The company reported no operating revenue and had not begun operating activities.
Financial results and position
| Metric | Q1 2021 / March 31, 2021 |
|---|---|
| Operating and formation costs | $482,211 |
| Change in warrant fair value | $5,301,167 noncash gain |
| Net income | $4,818,956, principally due to the warrant gain |
| Operating cash flow | $(293,498) |
| Cash outside trust | $1,285,361 |
| Cash held in trust | $316,250,000 |
| Total assets | $317,697,567 |
| Total liabilities | $6,013,237, including $5,837,625 of warrant liabilities |
| Debt | No long-term debt reported; a $275,000 related-party promissory note was repaid at the IPO closing |
Revenue and operating margins are not applicable because the company had no operating revenue. Cash used in investing activities was $316.25 million, reflecting the trust funding; financing activities provided $317.65 million. The company reported no material market or interest-rate risk at quarter-end, citing the short-term nature of trust investments.
Material changes and unusual items
- Foresight restated its February 12, 2021 financial statements to classify public and private warrants as derivative liabilities rather than equity. The reclassification increased the initial warrant liability by $11.14 million and reduced the amount presented as redeemable Class A stock. Changes in warrant fair value are recorded in earnings and may cause substantial quarter-to-quarter noncash volatility.
- Public and private shares subject to possible redemption were presented as temporary equity; $306.68 million was classified at redemption value at March 31.
- There is no meaningful prior-year quarterly comparison in the supplied filing; Foresight was incorporated in August 2020 and its IPO occurred in February 2021.
Outlook, risks, and contingencies
Management expected to use funds outside the trust primarily to identify and evaluate a target and said it did not expect to need additional funds for planned expenditures, while warning that cost overruns or a need to finance a business combination could require additional capital. No specific business-combination target or financial guidance is provided in the supplied text. The company was required to complete a combination by February 12, 2023, subject to any extension; failure to do so would trigger liquidation and redemption of public shares, while warrants could expire worthless.
Management identified a material weakness in internal control over financial reporting related to the warrant-accounting restatement and said remediation was under evaluation. It warned of potential future litigation or disputes, although it reported no known such litigation as of the filing date. Management also said COVID-19 could affect its financial position or target search, but the impact was not determinable. The filing reports no legal proceedings.
Most important facts to verify
- Confirm the intended company: this is Foresight Acquisition Corp.’s filing, not P3 Health Partners Inc.’s.
- Review the warrant-liability restatement, valuation assumptions, and the possibility of future earnings volatility.
- Track remediation of the disclosed material weakness and any subsequent developments in financial reporting controls.
- Verify the status, funding needs, and deadlines of any proposed business combination; this filing provides no specific target details.